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Summary. Background: Vascular smooth muscle cell (VSMC)
migration is a critical process in arterial remodeling. Purified
plasminogen activator inhibitor-1 (PAI-1) is reported to both
promote and inhibit VSMCmigration on two-dimensional (D)
surfaces. Objective: To determine the effects of PAI-1 and
vitronectin (VN) expressed by VSMC themselves on migration
through physiological collagenmatrices. Methods: We studied
migration of wild-type (WT), PAI-1-deficient, VN-deficient,
PAI-1/VN doubly-deficient (DKO) and PAI-1-transgenic (Tg)
VSMC through three-D collagen gels. Results: WT VSMC
migrated significantly slower than PAI-1- and VN-deficient
VSMC, but significantly faster thanDKOVSMC.Experiments
with recombinant PAI-1 suggested that basal VSMC PAI-1
expression inhibits migration by binding VN, which is secreted
byVSMCandbinds collagen.However, PAI-1-over-expressing
Tg VSMC migrated faster than WT VSMC. Reconstitution
experiments with recombinant PAI-1 mutants suggested that
the pro-migratory effect of PAI-1 over-expression required its
anti-plasminogen activator (PA) and LDL receptor-related
protein (LRP) binding functions, but not VN binding. While
promoting VSMC migration in the absence of PAI-1, VN
inhibited thepro-migratory effectof activePAI-1. Conclusions:
In isolation, VN and PAI-1 are each pro-migratory. However,
via formation of a high-affinity, non-motogenic complex, PAI-1
and VN each buffers the others pro-migratory effect. The level
of PAI-1 expression by VSMC and the concentration of VN in
extracellular matrix are critical determinants of whether PAI-1
and VN promote or inhibit migration. These findings help to
rectify previously conflicting reports and suggest that PAI-1/
VN stoichiometry plays an important role in VSMCmigration
and vascular remodeling.
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Intimal hyperplasia is a central process in acquired vascular
diseases, such as atherosclerosis and restenosis after balloon
angioplasty. A key step in intimal hyperplasia is the migration
of vascular smooth muscle cells (VSMC) from the media,
through the extracellular matrix (ECM) composed of colla-
gen, elastin and multiple other components, into the intima.
The plasminogen activation (PA) system plays a major role in
the regulation of cell migration and the development of
intimal hyperplasia [1,2]. Plasminogen activator inhibitor-1
(PAI-1) is the primary physiological inhibitor of tissue- and
urinary-type plasminogen activators (t-PA and u-PA, respec-
tively) and a major regulator of fibrinolysis [3]. PAI-1 is
present in plasma, platelets, endothelial cells, VSMC and the
ECM. PAI-1 expression in the vascular wall is increased in
several human vascular diseases characterized by neointima
formation, suggesting that PAI-1 may regulate the develop-
ment of intimal hyperplasia [4,5]. PAI-1 binds vitronectin
(VN), an adhesive glycoprotein present in ECM that plays key
roles in cell adhesion and migration [6,7]. Binding of PAI-1
inhibits VNs interactions with its receptors on VSMC,
thereby inhibiting VSMC adhesion and migration [8,9].
However, PAI-1 has also been reported to promote VSMC
migration by binding to low-density lipoprotein receptor-
related protein (LRP), which is expressed on the surface of
VSMC [10]. When bound to VN, PAI-1s LRP binding site
remains in an encrypted state that does not bind LRP [11,12].
Hence, PAI-1 and VN regulate each others functions and are
poised to play key roles in VSMC migration and intimal
hyperplasia.
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While PAI-1 can either promote or inhibit VSMC
migration in vitro, depending on experimental conditions,
the net effect of PAI-1 on VSMC migration in vivo is
unknown. However, it is difficult to study VSMC migration
in vivo. Intimal hyperplasia cannot be used as a surrogate
because it depends not only on VSMC migration, but also
on VSMC proliferation and apoptosis and other processes
independent of VSMC. Prior in vitro studies of the roles of
PAI-1 and VN in VSMC migration have involved two-
dimensional (2-D) culture systems in which cells are seeded
on plastic surfaces coated with a purified matrix molecule
and purified PAI-1 is added [8–10]. Two-D cell culture
systems, such as the modified Boyden chamber (MBC), are
useful, but do not adequately reproduce the complex, three-
D ECM in which VSMC migrate in vivo [13,14], nor does
addition of recombinant PAI-1 to cells coated on VN or
other purified matrix components give adequate insight into
the functional significance of PAI-1 and VN produced by
VSMC themselves. Within the vascular wall, an environment
not directly accessible to plasma, the pool of PAI-1 produced
by VSMC is likely to be a major determinant of the overall
effect of PAI-1 on VSMC migration. However, the impact of
PAI-1 expression by VSMC on their migration under
physiological conditions has not been studied. To address
these issues, we examined the migration of VSMC with
variable levels of PAI-1 expression through three-D collagen
matrices. Given that VSMC express VN in vivo [15], as well
as the key role of VN in determining PAI-1 function, we also
studied the effects of VSMC VN expression and ECM VN
concentration on PAI-1s migratory properties.
Materials and methods
Proteins
Recombinant human PAI-1 was expressed and purified as
described previously [16]. The following mutants were used: (i)
PAI-1-14-1b (PAI-1 N150H, K154T, Q319L and M354I),
which inhibits u-PA and t-PA and binds VN with wild-type
(WT) activities [17]; however, unlike WT PAI-1 (which has a
half-life of 1–2 h under physiological conditions), PAI-1-14-1b
is resistant to conversion to the inactive (i.e. latent) form (half-
life > 140 h), and hence is useful in experiments examining
PAI-1 function over longer periods of time, as in the
migration assay described below. Throughout the present
study PAI-1-14-1b is referred to as PAI-1-WT; (ii) PAI-1-R
(T333R, A335R), a reactive center mutant that binds VN
normally, but has no detectable anti-proteolytic activity and
cannot assume a latent conformation [16]; (iii) PAI-1-AK
(PAI-1 N150H, K154T, Q319L, M354I, R101A and Q123K),
an active, stable mutant with no detectable VN binding
[16,18]; and (iv) PAI-1-R76E, I91L, an active, stable mutant
that does not bind LRP [19]. Latent human PAI-1 and mouse
multimeric VN were from Molecular Innovations. Platelet-
derived growth factor (PDGF)-BB and rat tail collagen type 1
were from Millipore.
Animals
C57Bl/6J mice were from Jackson Labs. C57Bl/6J-congenic
PAI-1-deficient (Pai1)/)) mice were a gift fromPeter Carmeliet,
University of Leuven, Leuven, Belgium [20]. C57Bl/6J-con-
genic VN-deficient (Vn)/)) mice and PAI-1-transgenic (Tg)
mice that over-express PAI-1 under the control of the CMV
promoter were from David Ginsburg, University of Michigan
[21,22]. Mice received standard chow. All experiments were
approved by the University of Missouri Office of Animal
Resources.
Cell culture
VSMC were isolated from mouse aortas and grown in culture
as described previously [23]. VSMC (passage 2–3) were
cultured in Dulbeccos modified Eagles medium (DMEM)
supplemented with 20% fetal bovine serum (FBS) and
gentamycin/amphotericin B. After achieving 70–90% conflu-
ency, cells were serum starved (0.2% FBS) overnight. Cells
were harvested by trypsin digestion, washed and resuspended
in 0.2% FBS for use in the three-D cell migration assay. To
determine if genetic deletion of PAI-1, VN or both affected the
general migration properties of cultured VSMC, we performed
control experiments in which WT, PAI-1-deficient, VN-
deficient and PAI-1/VN doubly-deficient VSMC were seeded
on collagen-coated porous membranes in a modified Boyden
chamber and VSMC migration through pores into the lower
chamber was stimulated with PDGF-BB [24]. At 6 h after
seeding of VSMC on collagen there were no significant
differences in migration between the four groups of cells (data
not shown), suggesting that genetic deletion of PAI-1 and/or
VN did not significantly alter the general migration properties
of VSMC.
Three-D cell migration assay
Collagen gels were prepared as described previously [25], except
that the final collagen concentration was 2.2 mg mL)1. Poly-
merizing collagen mixture (30 lL) was pipetted into the upper
chambers of 24-well Transwell inserts (Corning)whose bottoms
consistedofporous (8 lmporediameter)membranes.Aftergels
polymerized, DMEMmedium (200 lL) containing 0.2% fetal
bovine serum (FBS) andmurine VSMC (105) were added to the
upper chamber. Inserts were placed into lower chamber wells
filled withDMEM (600 lL) containing 2.5%FBS and PDGF-
BB (20 ng mL)1), which stimulate VSMC migration through
the collagen gel into the lower chamber. After 72 h of standard
cell culture conditions, inserts were removed, collagen gels were
scraped away and membranes were stained with Diff-Quick
(Siemens Healthcare Diagnostics, Newark, DE, USA). The
lower-chamber sideof themembrane, towhichcells thatmigrate
through the collagen gel and pores adhere, was visualized
en-face with a microscope and cells were counted. In some
experiments VN or recombinant PAI-1 was added to polymer-
izing collagen solutions and upper chamber culture media.
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Western blotting and ELISA
VSMC were grown to confluency. Conditioned media (CM)
was removed and cells were washed twice with phosphate-
buffered saline and lysed by addition of sodium dodecyl
sulphate (SDS) solution [26]. The lysate was centrifuged to
remove insoluble material. Total protein concentration of the
supernatant was measured with the BCA reagent. Samples
(30 lg total protein) were subjected to SDS-polyacrylamide gel
electrophoresis (PAGE) and Western blotting with rabbit
antibodies raised against murine PAI-1 (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) and beta-actin (Cell Signaling
Technology), as described previously [27]. PAI-1 concentration
in CM was measured using an ELISA for murine PAI-1
(Innovative Research). Results were normalized to total
protein concentration of CM.
Data analyzes
Duplicate or triplicate wells were performed for each set of
experimental conditions in each experiment and mean results
were calculated. A control group consisting ofWTor untreated
cells was included in each experiment. As indicated, results are
reported as% control. All experiments were performed at least
in triplicate, with results reported as mean ± standard error of
mean. Experimental groups were compared using two-tailed
Students t-test or one-way analysis of variance.
Results
Isolated deficiency PAI-1 or VN increases VSMC migration
through collagen, whereas combined deficiency of PAI-1 and
VN inhibits migration
To study the functions of PAI-1 and VN expressed by VSMC
duringmigration through collagen, we compared themigration
of VSMC isolated from WT, Pai1)/) and Vn)/) mice. PAI-1-
deficient VSMC migrated significantly faster than WT VSMC
(Fig. 1), suggesting that under physiological conditions the
dominant effect of basal PAI-1 expression by VSMC is anti-
migratory. VN-deficient VSMC also migrated significantly
faster than WT VSMC, although significantly slower than
PAI-1-deficient VSMC (Fig. 1). To examine the impact of
combined PAI-1 and VN deficiency on VSMC migration, we
crossedPai1)/)mice andVn)/)mice to generate double-knock-
out mice, from which we established cultured lines of VSMC.
While VSMC lacking only PAI-1 or VN each migrated faster
thanWTVSMC,VSMC lacking both PAI-1 and VNmigrated
significantly slower than WT VSMC (Fig. 1). These results
suggested that a basal level of PAI-1 expression by VSMC
inhibited migration only if VSMC VN expression is preserved.
However, genetic deletion of VN converted the effect of VSMC
PAI-1 expression to pro-migratory, as evidenced by comparing
themigratory properties of VN-deficient VSMC (which express
PAI-1) to those of VSMC lacking both PAI-1 and VN. These
results also suggested that basal VN expression inhibited
VSMC migration when PAI-1 expression was preserved, but
promoted migration when PAI-1 was genetically deleted, as
evidenced by comparing the migratory properties of PAI-1-
deficient VSMC (which express VN) to those of VSMC lacking
both PAI-1 and VN.
Recombinant PAI-1 mutants promote and inhibit VSMC
migration through collagen by distinct mechanisms
We added several forms of recombinant PAI-1 (each at
1 lg mL)1) to three-D migration assays containing PAI-1-
deficient VSMC to enable us to study the impact of specific
functional defects in PAI-1 on VSMC migration through
collagen. PAI-1-WT significantly increased migration of PAI-
1-deficient VSMC (Fig. 2). PAI-1-AK (which inhibits PAs, but
does not bind VN) also significantly increased migration of
PAI-1-deficient VSMC. However, PAI-1-R76E, I91L (which
inhibits PAs and binds VN, but does not bind LRP) did not
increase PAI-1-deficient VSMC migration, rather producing a




























Fig. 1. Deficiency of plasminogen activator inhibitor-1 (PAI-1) or
vitronectin (VN) enhances vascular smooth muscle cell (VSMC)
migration, whereas combined PAI-1/VN deficiency inhibits migration.
The number of VSMC migrating through the three-D collagen matrix in
72 h was determined, with results expressed as % control [i.e. wild-type
(WT) VSMC]. *P < 0.001 vs. WT; P < 0.01 vs. Vn)/) VSMC;




























Fig. 2. Effects of recombinant plasminogen activator inhibitor-1 (PAI-1)
on vascular smooth muscle cell (VSMC) migration. All cells used in this
experiment were PAI-1 deficient. *P < 0.002 vs. control PAI-1-deficient
VSMC that were not treated with recombinant PAI-1 (None group).
R76E designates PAI-1-R76E, I91L.
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that active PAI-1 can stimulate VSMC migration through
collagen by a mechanism that requires LRP binding, but does
not require binding to VN, which is secreted by VSMC and
binds collagen [28]. PAI-1-R (which does not inhibit PAs, but
binds VN with normal affinity) significantly inhibited migra-
tion of PAI-1-deficient VSMC (Fig. 2). Latent PAI-1, which
does not inhibit PAs and has low binding affinity for VN, had
no significant effect on migration of PAI-1-deficient VSMC.
Together, these results suggested that PAI-1 can inhibit VSMC
migration through collagen under physiological conditions by
a VN-dependent mechanism that does not require protease
inhibition or LRP binding.
We also studied the effect of selected forms of recombinant
PAI-1 on migration of VN-deficient VSMC. PAI-1-WT
significantly increased migration of VN-deficient VSMC (i.e.
1.4 ± 0.1-fold compared to control matrices lacking PAI-1-
WT, P < 0.001), further suggesting that enhancement of
VSMC migration by PAI-1-WT does not require VN binding.
PAI-1-R had no significant effect on migration of VN-deficient
VSMC (data not shown), further suggesting that inhibition of
VSMC migration by PAI-1-R requires VN binding.
ECM PAI-1 and VN increase migration of WT VSMC, but
each factor inhibits the others pro-migratory effect
Concentrations of PAI-1 and VN in the vascular wall are
increased in somehumandisease states [4,29].We supplemented
collagen matrices with PAI-1-WT (1 lg mL)1 = 23.3 nM),
multimeric VN (10 lg mL)1 = 133 nM), or both PAI-1-WT
and VN to examine the effects of increased ECM concentra-
tions of these factors on VSMC migration. PAI-1-WT signif-
icantly increased migration of WT VSMC through collagen
(Fig. 3, bar 1 vs. 2). VNalso significantly increasedmigration of
WTVSMC through collagen (Fig. 3, bar 1 vs. 3). These results
suggested that increased an ECM concentration of either active
PAI-1 or VN promotes VSMC migration. However, addition
of both PAI-1-WT and VN to collagen matrices resulted in no
significant change in VSMCmigration compared with collagen
matrices to which neither factor was added (Fig. 3, bar 1 vs. 4),
suggesting that active PAI-1 and VN can each inhibit the pro-
migratory effect of the other. Consistent with this hypothesis,
addition of VN (10 lg mL)1) to collagen matrices reduced the
migration of VN-deficient VSMC (which express PAI-1) by
57.2 ± 6.6% (n = 3,P < 0.001).We also examined the effect
of adding a higher concentration of PAI-1-WT (5 lg mL)1 =
116 nM) along with VN (10 lg mL)1) on migration of WT
VSMC. Under these conditions VSMC migration was signif-
icantly increased compared with control conditions lacking
addition of either factor (Fig. 3, bar 1 vs. 5). These results
suggested that a stimulatory effect of active PAI-1 on VSMC
migration can be observed in the presence of VN if the PAI-1
concentration is sufficiently high.
PAI-1 over-expression increases VSMC through collagen,
but VN blunts this effect
Based on our findings that addition of active PAI-1 to collagen
matrix promoted VSMC migration, we hypothesized that
genetic over-expression of PAI-1 would also enhance VSMC
migration. To test this hypothesis, we isolated aortic VSMC
from PAI-1-Tg mice. SDS-PAGE/Western blot analysis of
cultured PAI-1-Tg VSMC confirmed that they expressed
significantly more PAI-1 than WT VSMC (Fig. 4). Consistent
with these data, the PAI-1 concentration in CM of confluent
PAI-1-Tg VSMC was significantly higher than that of conflu-
ent WT VSMC (430 ± 88.1 vs. 154 ± 13.3 ng PAI-1 mg)1
total protein, respectively, n = 4 per group, P = 0.02),
whereas PAI-1 was undetectable in CM of confluent PAI-1-
deficient VSMC. PAI-1-Tg VSMC migrated through collagen
significantly faster than WT VSMC (Fig. 5), suggesting that
over-expression of PAI-1 by VSMC, as occurs in human
vascular diseases [4], promotes migration through collagen.We
also compared the migration of WT and PAI-1-Tg VSMC in
collagen matrices supplemented with VN (10 lg mL)1). Under
these conditions, the mean number of VSMC migrating
through the collagen+VN matrix in 72 h was higher for
PAI-1-Tg VSMC than WT VSMC, but the difference between
cell types did not achieve statistical significance (Fig. 5).
Furthermore, the ratio of the number of VSMC (i.e. PAI-1-
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Fig. 3. Extracellular matrix (ECM) plasminogen activator inhibitor-1
(PAI-1) and vitronectin (VN) increase migration of wild-type (WT)
vascular smooth muscle cell (VSMC), but inhibit each others pro-
migratory effect. X-axis values indicate concentrations of purified PAI-1
and VN (in nM) added in each experiment. *P < 0.001 vs. control (i.e. no




Fig. 4. Western blot analysis of plasminogen activator inhibitor-1 (PAI-1)
expression by cultured vascular smooth muscle cell (VSMC). Blots were
stripped and re-probed with anti-beta-actin antibody. Results shown are
representative of three independent experiments.
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(4.7 ± 0.8, n = 3) was significantly higher (P < 0.04) than
the ratio of PAI-1-Tg/WT VSMC that migrated through a
collagen+VN matrix (2.4 ± 0.5, n = 3). Together, these
results suggested that the pro-migratory effect of PAI-1 over-
expression is blunted by VN.
Discussion
In some studies PAI-1 has been reported to inhibit VSMC
migration [8], whereas in others PAI-1 has been reported to
promote VSMC migration [10]. These experiments involved
cell culture on two-D surfaces coated with purified VN or
another ECMmolecule and the addition of purified PAI-1 into
the experimental system. These discordant results beg the
questions, what is the net effect of PAI-1 on VSMC migration
under physiological conditions reflective of the arterial wall in
vivo, and how does PAI-1 produced by VSMC themselves
(which are likely to be the dominant source of PAI-1 within the
vascular media [30]) affect migration? To address these
questions, we studied the migration of VSMC with variable
levels of PAI-1 expression through three-D type I collagen
matrices, as type I collagen is a major component of the ECM
of the arterial media and intima [31]. We found that a basal
level of PAI-1 expression by VSMC inhibits migration through
collagen. It has been proposed that an important mechanism
underlying VSMC migration is activation of plasminogen by
uPA bound to its cell surface receptor, uPAR, resulting in
plasmin formation and digestion of ECM by plasmin or
metalloproteinases activated by plasmin. Under such a
scenario, PAI-1 would be expected to inhibit cell migration
by inhibiting uPA. However, we found no data to support this
mechanism in our experimental system (which contained
plasminogen because serum was added to culture media), as
reconstitution of PAI-1-deficient VSMC with recombinant
PAI-1-WT promoted, rather than inhibited, migration,
whereas PAI-1-R, a mutant devoid of anti-proteolytic activity,
mimicked the anti-migratory effect of endogenous PAI-1
expression. The capacity of PAI-1 to inhibit VSMC migration
through collagen was critically dependent onVN expression, as
demonstrated by the inability of PAI-1-R to inhibit migration
of VN-deficient VSMC, and by the contrasting effects of PAI-1
deficiency in VN-expressing vs. VN-deficient VSMC (Fig. 1).
VN engages integrins and uPAR on VSMC to promote
adhesion and migration [32]. Given that VN binds collagen
[28], our data suggest that VN secreted by VSMC bridges
collagen and cell surface VN receptors to promote migration,
and that PAI-1 can inhibit the migration of VSMC through
collagen by blocking the bridging function of VN.
Conversely, we found that PAI-1-Tg VSMC migrate
through collagen faster than WT VSMC do. The pro-
migratory effect of enhanced PAI-1 expression appeared to
depend on its anti-protease and LRP binding properties, as
addition of latent PAI-1, PAI-1-R, or PAI-1-R76E, I91L to
PAI-1-deficient VSMC did not stimulate migration, whereas
addition of PAI-1-WT or PAI-1-AK did. Previous studies
demonstrated that PAI-1 binds to uPA and other proteases,
which results in exposure of a cryptic LRPbinding site in PAI-1
[11]. Engagement of LRP by PAI-1 leads to internalization of
PAI-1-protease complex, LRP, and associated integrin, thereby
enabling cell detachment, which is necessary for migration
[19,33]. Our results demonstrate that VSMC PAI-1 expression
can stimulate migration under physiological conditions, but
apparently only if PAI-1 expression level is increased, as a pro-
migratory effect of PAI-1 was observed in PAI-1-Tg VSMC,
but not in WT cells. PAI-1 over-expression within the vascular
wall occurs in disease states characterized by migration of
VSMC from the media to the intima, including diabetes
mellitus and atherosclerosis [4,5]. Based upon our results we
hypothesize that basal PAI-1 expression by VSMC, as occurs
in a healthy artery, may inhibit intimal hyperplasia, whereas
enhanced PAI-1 expression by VSMC, as occurs in diabetes
mellitus and other disease states, may promote intimal
hyperplasia. Consistent with this hypothesis, Otsuka et al.
[34] observed less intimal hyperplasia in WTmice than in PAI-
1-deficient mice, whereas up-regulation of arterial PAI-1
expression by TGF-beta-1 promoted intimal hyperplasia.
Active PAI-1 spontaneously converts to a latent form, a
process that is delayed by binding of VN to PAI-1 [35]. While
Degryse et al. [10] observed that latent PAI-1 produced a
motogenic effect in VSMC cultured on a two-D surface, we did
not find any apparent effect of latent PAI-1 on VSMC
migration through three-D collagen, consistent with the low
affinity of latent PAI-1 for both VN and LRP [11].
Our experiments involving VN-deficient VSMC provide
important insights into the role of de novo VN expression by
VSMC in migration. While VN is generally considered to
promote VSMC migration though interactions with integrin
and non-integrin receptors onVSMC [6], we demonstrated that
VN can also exert an anti-migratory effect, as WT VSMC
migrated through collagen slower than VN-deficient VSMC


























Fig. 5. Plasminogen activator inhibitor-1 (PAI-1) over-expression
promotes vascular smooth muscle cell (VSMC) migration through colla-
gen matrix, but vitronectin (VN) blunts this effect. Wild-type (WT) and
PAI-1-Tg VSMC were seeded on collagen matrices and collagen matrices
containing VN (collagen + VN). Migration was assessed and expressed
as% control (WTVSMCmigrating through collagen). *P < 0.03 vs.WT
VSMC/collagen matrix. P = 0.09 vs. WT VSMC/collagen+VNmatrix.
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VN-deficient VSMC, and addition of VN to collagen matrices
blunted the pro-migratory effects of recombinant PAI-1-WT
and transgenic over-expression of PAI-1. However, we showed
that PAI-1-deficient VSMC (which express VN) migrate faster
than PAI-1/VN doubly-deficient VSMC did. Together these
experiments demonstrate that the anti-migratory effect of VN
depends on concomitant PAI-1 expression, whereas in the
absence of PAI-1, only a pro-migratory effect of VN is
observed. These results are consistent with the hypothesis that
when VN expression is low, up-regulation of PAI-1 expression
increases the pool of unbound, motogenic PAI-1, fostering
VSMC migration. However, when VN expression is high, up-
regulation of PAI-1 expression does not necessarily produce a
motogenic pool of PAI-1, as PAI-1 binds VN, blocking its
motogenic interactions with VSMC VN receptors, while at the
same time sequestering PAI-1 from LRP [11,12]. Nevertheless,
if PAI-1 expression is sufficiently high to saturate even
increased levels of VN, a motogenic pool of free PAI-1 can
be created. Some in vivo experiments involving PAI-1-knockout
mice concluded that PAI-1 promotes intimal hyperplasia
[36,37], others concluded that PAI-1 inhibits intimal hyperpla-
sia [38,39], and one study found no effect [40]. While multiple
factors are likely to have contributed to these variable results, it
is possible that variability in VN expression between different
vascular injury models [29] and mouse strains could have
accounted for the variable effects of PAI-1 on neointima
formation in these studies. Conversely, differences in PAI-1
expression level between experimental models may have
contributed to the generation of conflicting reports that VN
promotes [36] and inhibits [39] intimal hyperplasia after
vascular injury.
In summary, we examined the roles of PAI-1 and VN
expression by VSMC in their migration through physiological
collagen matrices. Based on our results we propose the
following paradigm. In isolation, VN and PAI-1 are each
pro-migratory, the former by fostering cell adhesion, the latter
by fostering cell detachment – both of which are necessary in
coordinated fashion for VSMC migration. However, via
formation of a high-affinity, non-motogenic complex, PAI-1
and VN each buffers the others pro-migratory effect (Fig. 6).
Binding of PAI-1 to VN blocks VNs interactions with its
VSMC receptors, thereby inhibiting cell adhesion. Binding of
VN to PAI-1 can inhibit exposure of PAI-1s LRP binding site
andmay sequester PAI-1 from interactingwith VSMC, thereby
inhibiting PAI-1s pro-migratory properties [11,12]. Hence,
PAI-1 and VN exhibit a distinct functional interdependence in
regulating VSMCmigration [41]. The level of PAI-1 expression
by VSMC and the concentration of VN in ECM are critical
determinants of whether PAI-1 (or VN) promotes or inhibits
migration. If VN expression is low, free PAI-1 is more likely to
accumulate and stimulate VSMC migration after exposing its
LRP binding site. However, if VN expression is high, PAI-1 is
more likely to bind VN, thereby producing an anti-migratory












Fig. 6. Pro- andanti-migratory effects of plasminogenactivator inhibitor-1 (PAI-1) andvitronectin (VN)onvascular smoothmuscle cell (VSMC).VNbinds
collagen and stimulates (+) VSMCmigration by interacting with aVb3 and uPA receptor (uPAR). PAI-1 stimulates VSMC migration by binding to a
plasminogen activator (PA), which exposes an low density lipoprotein receptor-related protein (LRP) binding site on PAI-1, leading to engagement of the
complex with LRP, amotogenic receptor. Binding of PAI-1 to VN yields a complex that is not motogenic, providing amechanism for each factor to inhibit
the pro-migratory effect of the other.
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Conversely, if PAI-1 expression is low, unbound VN can
promoteVSMCmigration, whereas if PAI-1 expression is high,
VN is more likely to be consumed into PAI-1-VN complex,
thereby inhibiting PAI-1s pro-migratory function. This para-
digm establishes the important role of PAI-1/VN stoichiometry
in determining each factors vascular effects. While our in vitro
assay allowed us to study VSMC migration under physiolog-
ical conditions, it did not reproduce several important factors
present in vivo, including complex, multi-component ECM, cell
types other than VSMC, and other factors that regulate cell
migration, including thrombin, metalloproteinases, and cyto-
kines. Therefore, animal studies will be necessary to further test
the hypothesis that PAI-1/VN stoichiometry is an important
regulator of arterial remodeling.
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